Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a m
- PDF / 1,919,886 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 20 Downloads / 222 Views
REVIEW ARTICLE
Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials Zheng-rui Fan 1,2,3 & Jian-xiong Ma 1,2 & Ying Wang 1,2 & Heng-ting Chen 1,2,3 & Shuang Lang 1,2 & Xin-long Ma 1,2 Received: 5 August 2020 / Revised: 22 October 2020 / Accepted: 28 October 2020 # International League of Associations for Rheumatology (ILAR) 2020
Abstract This study aims to evaluate the efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis. Randomized controlled phase III trials (RCTs) that evaluated the efficacy and safety associated with tanezumab for knee or hip OA were systematically identified by searching electronic databases, including Cochrane Library, PubMed, and Embase, for 30 years from December 1990 up to July 2020. Ten relevant studies were included in our meta-analysis. The research was reported based on the preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines to ensure the reliability and verity of results. Our study showed that the tanezumab groups were more effective than the placebo groups in terms of mean change from the baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain (P < .00001), WOMAC physical functional (P < .00001), and patient’s global assessment (PGA) (P < .00001). Discontinued due to adverse events (AEs) (P < .00001), serious AEs (P = .02), abnormal peripheral sensations (both P < .00001), and peripheral neuropathy (P < .002) in tanezumab groups were significantly higher than that in control groups. Compared with placebo, tanezumab can effectively relieve pain and improve WOMAC physical function and patient’s global assessment (PGA) in knee and hip osteoarthritis. Meanwhile, adverse events are transient in nature and generally well-tolerated. However, we still need large-sample, high-quality studies to investigate the long-term safety of tanezumab to give the conclusion. Keywords Hip . Knee . Nerve growth factor . Osteoarthritis . Randomized controlled trials . Tanezumab
Introduction Osteoarthritis (OA), a leading cause of chronic joint pain and disability, makes a serious impact on the health of the
Jian-xiong Ma contributed equally to this work. Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10067-02005488-4. * Xin-long Ma [email protected] 1
Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin 300050, People’s Republic of China
2
Tianjin Hospital, Tianjin University, Tianjin 300211, People’s Republic of China
3
Tianjin Medical University, Tianjin 300211, People’s Republic of China
individuals [1]. Patients with moderate to severe OA often suffer from excruciating pain with chronic inflammation and reduced range of motion, especially in the knee or hip [2]. Conventional treatment of hip or knee OA includes nonpharmacologic therapies and pharmacologic therapies
Data Loading...
